The insider sales are routine post-offering liquidity events, no bearish signal. Monitor the upcoming Phase 3 data readout for deucrictibant (expected H2 2026) as the primary catalyst. The $107.5M raise provides runway into H1 2028, reducing near-term financing risk.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 22 $29.68entry
- T+1 · 6mo ago +0.67%α +0.09% · $29.88
- T+5 · 6mo ago −1.95%α −3.63% · $29.10
- T+20 · 5mo ago +9.47%α +10.88% · $32.49
- T+60 · 3mo ago +21.63%α +18.44% · $36.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Five Pharvaris insiders, including the CEO and CCO, sold a total of ~$1.08M in open-market sales over a 7-day window, following a $107.5M equity offering that closed 14 days prior. The sales represent ~0.05% of the $2.1B market cap, a trivial amount, and are likely liquidity-driven after the offering's lock-up expiration rather than a bearish signal on the pipeline.
Key Financial Metrics
Key Facts
- Five insiders sold a combined ~36,300 shares for ~$1.08M in open-market transactions (May 13-20, 2026).
- CEO Berndt Modig sold 2,292 shares for ~$67K; CCO Wim Souverijns sold 10,000 shares for ~$299K.
- Total sales equal ~0.05% of Pharvaris' $2.1B market cap, well below the 0.1% materiality threshold.
- The cluster follows a $107.5M underwritten public offering (424B5, May 8, 2026) that extended cash runway into H1 2028.
- Director Elisabeth Bjork also exercised 10,000 options at $8.05/share ($80,500 cost) and sold the shares for $293K, a net cash-out of ~$213K.
Financial Impact
Total insider sales of ~$1.08M, or 0.05% of market cap, immaterial relative to company size.
Risk Factors
- Phase 3 clinical trial failure for deucrictibant in HAE would be a material negative catalyst.
- Further insider selling at higher volumes (>0.5% of market cap) could signal loss of confidence.
- Cash burn rate may accelerate if US commercialization costs ramp faster than expected.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PHVS-1779476076663 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers